Results and Data Sample Clauses

Results and Data. Provider shall inform the affected personnel of the results of each test performed within 48-72 hours from administering each test.

Results and Data. Somanta shall be provided with, and shall have the right to access and use, all data collected or generated in the course of conducting the Clinical Trial, including, without limitation, records, reports, specimens, and other work product generated by or on behalf of any principal investigator in the course of performing the Clinical Trial, whether CONFIDENTIAL TREATMENT REQUESTED in written, graphic or electronic form or contained in any computer database or in any computer readable form ("Data"). CRICC agrees to attempt to require the principal investigator to ensure the accuracy, completeness, legibility and timeliness of all Data provided.

Results and Data. 9. Výsledky a údaje. Clinician Site and the Principal Investigator warrant that all CRFs submitted to Company will be complete and will accurately reflect the results of the Study. The parties acknowledge and agree that the data collected by Company in the performance of the Study shall be owned by Company or Sponsor, as agreed among themselves. Consistent with the terms of this Agreement, Company and Sponsor shall have the exclusive right to aggregate, deidentify and anonymize the data obtained from the Study performed pursuant to this Agreement. Clinician Site and the Principal Investigator shall have no rights in the results and data. Clinician Site shall be solely responsible for all payments due to the Principal Investigator and/or Clinician Site’s employees and/or collaborators according to the applicable law for any inventions transferred to Company or Sponsor or their designee. In any case, all data, information and documents provided to Clinician Site and the Principal Investigator by Company or Sponsor or any of their affiliates, whether in paper, oral, electronic or other form, shall remain the sole property of Company or Sponsor (and/or their affiliates), as the case may be. Klinické pracoviště a hlavní zkoušející ručí za to, že všechny záznamy subjektu hodnocení předložené společnosti budou úplné a budou přesně odrážet výsledky studie. Strany potvrzují a souhlasí s tím, že údaje shromážděné společností při provádění studie patří společnosti nebo zadavateli podle jejich vzájemné dohody. V souladu s podmínkami této smlouvy bude mít společnost a zadavatel výhradní právo k agregování, deidentifikování a anonymizování údajů získaných ze studie provedené podle této smlouvy. Klinické pracoviště a hlavní zkoušející nebudou mít žádná práva související s výsledky a údaji. Výhradní odpovědnost za všechny platby ve prospěch hlavního zkoušejícího a/nebo zaměstnanců či spolupracovníků klinického pracoviště v souladu s platnými právními předpisy nese za jakékoliv vynálezy převedené společnosti nebo zadavateli nebo jimi pověřené osobě klinické pracoviště. V každém případě zůstanou všechny údaje, informace a dokumenty poskytnuté klinickému pracovišti a hlavnímu zkoušejícímu společností nebo zadavatelem nebo přidruženými stranami, ať už písemně, ústně, elektronicky nebo jinak, výhradním majetkem společnosti nebo zadavatele (a/nebo přidružených stran), podle jejich povahy.

Results and Data. All Clinical Data shall be owned by the Party that conducts the applicable Clinical Trial. Without limiting the foregoing, any Clinical Data arising from the BeiGene Ongoing Clinical Trials (the “BeiGene Ongoing Clinical Trial Data”) shall be owned by BeiGene and included in BeiGene Know-How and the licenses granted to Novartis pursuant to Section 9.1.

Results and Data. The data and test results of research and development conducted as a result of this Agreement are confidential, proprietary and of great value to the parties. The data and test results are subject to the terms of Article X of this Agreement which are not inconsistent with this Section 11.1. ▇▇▇▇▇ ▇▇▇▇ shall not use or disclose the data or test results for any purpose other than in accordance with the terms of this Agreement. The data and test results shall be deemed to embody Technology. The data and test results shall be owned solely by ADOLOR, and ADOLOR shall be free to use the data and test results for any purpose, including but not limited to disclosure to a third party.

Results and Data. All Clinical Data shall be owned by the Party that conducts the applicable Clinical Trial. Without limiting the foregoing, any Clinical Data arising from the Initial Global Studies (other than the Novartis-Initiated Trials) and any New Registrational Clinical Trial and New Other Clinical Trial for which BeiGene is the Sponsoring Party and for which Novartis has provided a Novartis Study Design Agreement Notice (the “BeiGene Clinical Trial Data”) shall be owned by BeiGene and included in BeiGene Know-How and the Product Licenses granted to Novartis pursuant to Section 9.3.